{
  "ProtocolSection": {
    "IdentificationModule": {
      "NCTId": "NCT03877471",
      "OrgStudyIdInfo": {
        "OrgStudyId": "IOZ ChineseAS POI-2"
      },
      "Organization": {
        "OrgFullName": "Chinese Academy of Sciences",
        "OrgClass": "OTHER_GOV"
      },
      "BriefTitle": "Mesenchymal Stem Cells (MSCs) - Like Cell Transplantation in Women With Primary Ovarian Insufficiency",
      "OfficialTitle": "Safety Study of Human Embryonic Stem Cell Derived Mesenchymal Stem Cell (MSC)-Like Cells Transplantation in Women With Primary Ovarian Insufficiency (POI)",
      "Acronym": "MSCLCTWPOI"
    },
    "StatusModule": {
      "StatusVerifiedDate": "August 2021",
      "OverallStatus": "Active, not recruiting",
      "ExpandedAccessInfo": {
        "HasExpandedAccess": "No"
      },
      "StartDateStruct": {
        "StartDate": "April 3, 2019",
        "StartDateType": "Actual"
      },
      "PrimaryCompletionDateStruct": {
        "PrimaryCompletionDate": "July 1, 2020",
        "PrimaryCompletionDateType": "Actual"
      },
      "CompletionDateStruct": {
        "CompletionDate": "December 31, 2021",
        "CompletionDateType": "Anticipated"
      },
      "StudyFirstSubmitDate": "March 11, 2019",
      "StudyFirstSubmitQCDate": "March 14, 2019",
      "StudyFirstPostDateStruct": {
        "StudyFirstPostDate": "March 15, 2019",
        "StudyFirstPostDateType": "Actual"
      },
      "LastUpdateSubmitDate": "August 4, 2021",
      "LastUpdatePostDateStruct": {
        "LastUpdatePostDate": "August 5, 2021",
        "LastUpdatePostDateType": "Actual"
      }
    },
    "SponsorCollaboratorsModule": {
      "ResponsibleParty": {
        "ResponsiblePartyType": "Principal Investigator",
        "ResponsiblePartyInvestigatorFullName": "Hongmei Wang",
        "ResponsiblePartyInvestigatorTitle": "Professor",
        "ResponsiblePartyInvestigatorAffiliation": "Chinese Academy of Sciences"
      },
      "LeadSponsor": {
        "LeadSponsorName": "Chinese Academy of Sciences",
        "LeadSponsorClass": "OTHER_GOV"
      },
      "CollaboratorList": {
        "Collaborator": [
          {
            "CollaboratorName": "The First Affiliated Hospital of Zhengzhou University",
            "CollaboratorClass": "OTHER"
          },
          {
            "CollaboratorName": "National Natural Science Foundation of China",
            "CollaboratorClass": "OTHER_GOV"
          }
        ]
      }
    },
    "OversightModule": {
      "OversightHasDMC": "Yes",
      "IsFDARegulatedDrug": "No",
      "IsFDARegulatedDevice": "No"
    },
    "DescriptionModule": {
      "BriefSummary": "There is a high incidence of women suffering from Primary Ovarian Insufficiency (POI). So far, there was no treatment sufficient enough to cure POI. Cell therapy is a rapidly developing field and have shown immense promise in the treatment of ovarian dysfunction. In this study, the investigator will evaluate the safety of MSC-like cell therapy in women suffering from POI.",
      "DetailedDescription": "The purpose of this work is to explore the safety and preliminary efficacy of human embryonic stem cell derived MSC-like cell transplantation in women with POI. MSC-like cells were injected directly into bilateral ovaries under transvaginal ultrasound. Patients are subjected into 3 groups, with low (0.2×107), medium (0.5×107) and high dosage (1.0×107) of cells injection for each ovary. The outcomes of patients were followed after the injection every 2 weeks. The investigator mainly follow the safety indexes, and the level of sex hormone and signs of follicle growth will also be monitored. The growing follicles will be stimulated by exogenous hormone, followed by oocyte retrieval and in vitro fertilization (IVF)."
    },
    "ConditionsModule": {
      "ConditionList": {
        "Condition": [
          "Primary Ovarian Insufficiency"
        ]
      },
      "KeywordList": {
        "Keyword": [
          "Mesenchymal stem cell",
          "Transplantation",
          "Human embryonic stem cell",
          "Premature ovarian failure"
        ]
      }
    },
    "DesignModule": {
      "StudyType": "Interventional",
      "PhaseList": {
        "Phase": [
          "Phase 1"
        ]
      },
      "DesignInfo": {
        "DesignAllocation": "Non-Randomized",
        "DesignInterventionModel": "Sequential Assignment",
        "DesignInterventionModelDescription": "Patients will be subjected into 3 groups, with a low (0.2×107), medium (0.5×107) and high dosage (1.0×107) of cells transplantation for each ovary. The investigator will first carry out the low dosage group, and then the medium dosage group, based on the safety evaluation of the previous group, the high dosage group will be executed in the same way.",
        "DesignPrimaryPurpose": "Treatment",
        "DesignMaskingInfo": {
          "DesignMasking": "None (Open Label)"
        }
      },
      "EnrollmentInfo": {
        "EnrollmentCount": "28",
        "EnrollmentType": "Actual"
      }
    },
    "ArmsInterventionsModule": {
      "ArmGroupList": {
        "ArmGroup": [
          {
            "ArmGroupLabel": "Low dosage",
            "ArmGroupType": "Experimental",
            "ArmGroupDescription": "The low dosage will inject 2 million MSC-like cells (in 100ul suspension) for each ovary.",
            "ArmGroupInterventionList": {
              "ArmGroupInterventionName": [
                "Genetic: Cell therapy"
              ]
            }
          },
          {
            "ArmGroupLabel": "Medium dosage",
            "ArmGroupType": "Experimental",
            "ArmGroupDescription": "The medium dosage will inject 5 million MSC-like cells (in 100ul suspension) for each ovary.",
            "ArmGroupInterventionList": {
              "ArmGroupInterventionName": [
                "Genetic: Cell therapy"
              ]
            }
          },
          {
            "ArmGroupLabel": "High dosage",
            "ArmGroupType": "Experimental",
            "ArmGroupDescription": "The high dosage will inject 10 million MSC-like cells (in 100ul suspension) for each ovary.",
            "ArmGroupInterventionList": {
              "ArmGroupInterventionName": [
                "Genetic: Cell therapy"
              ]
            }
          }
        ]
      },
      "InterventionList": {
        "Intervention": [
          {
            "InterventionType": "Genetic",
            "InterventionName": "Cell therapy",
            "InterventionDescription": "Ovary injection with MSC-like cells through transvaginal ultrasound,3 injection points for each ovary.",
            "InterventionArmGroupLabelList": {
              "InterventionArmGroupLabel": [
                "High dosage",
                "Low dosage",
                "Medium dosage"
              ]
            }
          }
        ]
      }
    },
    "OutcomesModule": {
      "PrimaryOutcomeList": {
        "PrimaryOutcome": [
          {
            "PrimaryOutcomeMeasure": "Temperature",
            "PrimaryOutcomeDescription": "Body temperature of the participants will be measured fortnightly after injection.",
            "PrimaryOutcomeTimeFrame": "0-24 weeks"
          },
          {
            "PrimaryOutcomeMeasure": "Pulse",
            "PrimaryOutcomeDescription": "Pulse of the participants will be measured fortnightly after injection.",
            "PrimaryOutcomeTimeFrame": "0-24 weeks"
          },
          {
            "PrimaryOutcomeMeasure": "Breaths per minute",
            "PrimaryOutcomeDescription": "Breathing rate of the participants will be measured fortnightly after injection.",
            "PrimaryOutcomeTimeFrame": "0-24 weeks"
          },
          {
            "PrimaryOutcomeMeasure": "Blood pressure",
            "PrimaryOutcomeDescription": "Both systolic pressure and diastolic pressure of the participants will be assessed fortnightly after injection.",
            "PrimaryOutcomeTimeFrame": "0-24 weeks"
          }
        ]
      },
      "SecondaryOutcomeList": {
        "SecondaryOutcome": [
          {
            "SecondaryOutcomeMeasure": "Number of antral follicle",
            "SecondaryOutcomeDescription": "The number of antral follicles developing will be recorded by transvaginal ultrasound fortnightly after injection.",
            "SecondaryOutcomeTimeFrame": "0-24 weeks"
          },
          {
            "SecondaryOutcomeMeasure": "Follicle-stimulating hormone (FSH) serum level",
            "SecondaryOutcomeDescription": "Serum FSH level will be tested fortnightly after injection.",
            "SecondaryOutcomeTimeFrame": "0-24 weeks"
          },
          {
            "SecondaryOutcomeMeasure": "Estradiol (E2) serum level",
            "SecondaryOutcomeDescription": "Serum E2 level will be tested fortnightly after injection.",
            "SecondaryOutcomeTimeFrame": "0-24 weeks"
          },
          {
            "SecondaryOutcomeMeasure": "Anti-Mullerian hormone (AMH) serum level",
            "SecondaryOutcomeDescription": "Serum AMH level will be tested fortnightly after injection.",
            "SecondaryOutcomeTimeFrame": "0-24 weeks"
          },
          {
            "SecondaryOutcomeMeasure": "Ovarian volume",
            "SecondaryOutcomeDescription": "The ovarian volume will be recorded fortnightly by transvaginal ultrasound after injection.",
            "SecondaryOutcomeTimeFrame": "0-24 weeks"
          }
        ]
      }
    },
    "EligibilityModule": {
      "EligibilityCriteria": "Inclusion Criteria:\n\nUnder 40 years of age;\nHave established regular menstrual cycle, oligomenorrhea / amenorrhea ≥ 4 months;\nFSH (Follicle-Stimulating Hormone) > 25 IU/mL;\nBilateral ovaries are visible by ultrasound;\nHave fertility requirement, husband has sperms;\nWilling to sign the Informed Consent Form.\n\nExclusion Criteria:\n\nPrimary amenorrhea;\nHistory of serious drug allergy or allergic constitution;\nThrombophlebitis and thromboembolia, past and present;\nAcute or chronic infection, hematologic disease, angiocardiopathy, pulmonary disease, liver disease, nephropathy, pancreas disease\nAutoimmune disease, history of severe familial genetic disease, etc.\nAnatomical abnormality of reproductive system;\nContraindications for pregnancy;\nSpouse azoospermia;\nHIV+, hepatitis B, C;\nThyroid dysfunction;\nHistory of previous malignant or ovarian tumors, history of ovarian therapy;\nAbnormal karyotyping (e.g. turner syndrome, fragile X syndrome);\nDuring pregnancy or lactation;\nAlcohol or other substance abuse;\nMental disease, communicate obstruction;\nUnwilling to comply with follow-up schedule or want to take other treatment during the follow-up period;\nAttending doctor consider inappropriate to take part in.",
      "HealthyVolunteers": "No",
      "Gender": "Female",
      "GenderBased": "Yes",
      "GenderDescription": "Only female will be enrolled.",
      "MaximumAge": "40 Years",
      "StdAgeList": {
        "StdAge": [
          "Child",
          "Adult"
        ]
      }
    },
    "ContactsLocationsModule": {
      "OverallOfficialList": {
        "OverallOfficial": [
          {
            "OverallOfficialName": "Hongmei Wang, Doctor",
            "OverallOfficialAffiliation": "Institute of zoology, Chinese Academy of Sciences",
            "OverallOfficialRole": "Principal Investigator"
          }
        ]
      },
      "LocationList": {
        "Location": [
          {
            "LocationFacility": "The First Affiliated Hospital of Zhengzhou University",
            "LocationCity": "Zhengzhou",
            "LocationState": "Henan",
            "LocationZip": "450052",
            "LocationCountry": "China"
          }
        ]
      }
    },
    "IPDSharingStatementModule": {
      "IPDSharing": "No",
      "IPDSharingDescription": "The investigator have not recruited enough participant yet, till now, most of them would like to keep the individual participant data classified."
    }
  },
  "DerivedSection": {
    "MiscInfoModule": {
      "VersionHolder": "January 20, 2022"
    },
    "ConditionBrowseModule": {
      "ConditionMeshList": {
        "ConditionMesh": [
          {
            "ConditionMeshId": "D000016649",
            "ConditionMeshTerm": "Primary Ovarian Insufficiency"
          },
          {
            "ConditionMeshId": "D000008594",
            "ConditionMeshTerm": "Menopause, Premature"
          }
        ]
      },
      "ConditionAncestorList": {
        "ConditionAncestor": [
          {
            "ConditionAncestorId": "D000010049",
            "ConditionAncestorTerm": "Ovarian Diseases"
          },
          {
            "ConditionAncestorId": "D000000291",
            "ConditionAncestorTerm": "Adnexal Diseases"
          },
          {
            "ConditionAncestorId": "D000006058",
            "ConditionAncestorTerm": "Gonadal Disorders"
          },
          {
            "ConditionAncestorId": "D000004700",
            "ConditionAncestorTerm": "Endocrine System Diseases"
          }
        ]
      },
      "ConditionBrowseLeafList": {
        "ConditionBrowseLeaf": [
          {
            "ConditionBrowseLeafId": "M25022",
            "ConditionBrowseLeafName": "Premature Birth",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M18172",
            "ConditionBrowseLeafName": "Primary Ovarian Insufficiency",
            "ConditionBrowseLeafAsFound": "Primary Ovarian Insufficiency",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M10729",
            "ConditionBrowseLeafName": "Menopause, Premature",
            "ConditionBrowseLeafAsFound": "Primary Ovarian Insufficiency",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M12124",
            "ConditionBrowseLeafName": "Ovarian Diseases",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M2795",
            "ConditionBrowseLeafName": "Adnexal Diseases",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M8315",
            "ConditionBrowseLeafName": "Gonadal Disorders",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M7014",
            "ConditionBrowseLeafName": "Endocrine System Diseases",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "T6036",
            "ConditionBrowseLeafName": "Menopause",
            "ConditionBrowseLeafRelevance": "low"
          }
        ]
      },
      "ConditionBrowseBranchList": {
        "ConditionBrowseBranch": [
          {
            "ConditionBrowseBranchAbbrev": "BXS",
            "ConditionBrowseBranchName": "Urinary Tract, Sexual Organs, and Pregnancy Conditions"
          },
          {
            "ConditionBrowseBranchAbbrev": "All",
            "ConditionBrowseBranchName": "All Conditions"
          },
          {
            "ConditionBrowseBranchAbbrev": "BC19",
            "ConditionBrowseBranchName": "Gland and Hormone Related Diseases"
          }
        ]
      }
    }
  }
}